Collaboration will combine Vyriad’s lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ — Vyriad, Inc., a clinical-stage biotechnology company developing the next...
WALTHAM, Mass., Sept. 24, 2024 /PRNewswire/ — Nanomosaic, the multiplex and multi-omic marker analysis company, today announced major technical and commercial milestones for its Tessie system and assays optimized for gene therapy applications, evidencing the...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has partnered with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P...
Through Pfizer Ignite, Acepodia will gain access to Pfizer’s resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer Ignite will also provide strategic advisory support for...
Microcarrier-microbioreactor setup and protocol. Credit: Journal of Translational Medicine (2024). DOI: 10.1186/s12967-024-05373-7 A new approach to manufacturing cells that secrete and deliver therapies to specific parts of the body has taken a big step toward one...
